香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1763） 持續關連交易 重續持續關連交易 重續持續關連交易 茲提述本公司(i)日期為2023年3月30日之公告，內容有關（其中包括）訂立2023 年金融服務協議；(ii)日期為2023年10月31日之公告，內容有關（其中包括）訂 立2023年供應協議、2023年購買協議、2023年租賃協議、2023年碳-14供應協 議、2023年鈷-60供應協議、2023年諮詢協議及2023年工程建設服務框架協議， 及(iii)日期為2024年8月30日之公告，內容有關（其中包括）修訂2023年工程建 設服務框架協議、2023年購買協議及2023年供應協議項下的年度上限。 由於該等協議均將於2025年12月31日屆滿，為繼續該等協議項下進行的各項交 易，董事會已決議重 ...

Core Viewpoint - China Tongfu (01763) announced a collaboration with Beijing Normal University to sign a patent transfer agreement and a cooperation agreement for the fluorine-18 labeled beta-amyloid imaging agent project, aimed at early diagnosis of Alzheimer's disease [1] Company Summary - The fluorine-18 labeled beta-amyloid imaging agent is a new drug developed by a team led by Professor Cui Mengchao from Beijing Normal University in collaboration with China Tongfu, possessing complete independent intellectual property rights [1] - The drug has shown significant improvement in clinical applications, demonstrating a notable reduction in non-specific uptake in brain white matter compared to similar products approved by the FDA [1] Industry Summary - The signing event marks a significant milestone in the collaboration between academia and industry, emphasizing the importance of transforming scientific research outcomes into national strategic productivity [1] - The nuclear medicine industry is currently experiencing a golden development period, with China Tongfu emerging as a core player in the field due to its deep industry experience and distinctive industrial characteristics [1] - Future collaborations will focus on accelerating the clinical transformation of core results and building a talent cultivation pathway, contributing to the global competition in new nuclear medicine technologies and supporting the high-quality development of China's nuclear medicine sector [1]

Core Viewpoint - The announcement highlights a significant collaboration between China Tongfu (01763) and Beijing Normal University, focusing on the patent transfer and academic-industry cooperation for the development of a new drug, Fluorine [F] Betazone, aimed at early diagnosis of Alzheimer's disease [1] Company Summary - China Tongfu's subsidiary, Atom High-Tech, signed a patent transfer agreement and an academic-industry cooperation agreement with Beijing Normal University on December 10, 2025 [1] - The Fluorine [F] Betazone project is a result of collaboration with Professor Cui Mengchao's team and is characterized by having complete independent intellectual property rights [1] - The drug shows significant improvement in clinical applications, demonstrating a notable reduction in non-specific uptake in brain white matter compared to similar products approved by the FDA [1] Industry Summary - The signing event represents a milestone in the collaboration between academia and industry, aimed at transforming scientific research outcomes into national strategic productivity [1] - The nuclear medicine industry is currently experiencing a golden development period, with Atom High-Tech positioned as a core player due to its deep industry experience and distinctive characteristics [1] - Future collaboration will focus on accelerating the clinical transformation of core results and building a talent cultivation pathway, contributing to global competition in new nuclear medicine technologies and supporting the high-quality development of China's nuclear medicine sector [1]

Core Viewpoint - The announcement highlights a significant collaboration between Yuanzi Gaoke Co., Ltd. and Beijing Normal University, focusing on the development and commercialization of a new drug, Fluorine-18 Betazide, aimed at early diagnosis of Alzheimer's disease [1] Group 1: Collaboration and Agreements - Yuanzi Gaoke signed a patent transfer agreement and a collaborative research agreement with Beijing Normal University on December 10, 2025 [1] - The collaboration is a culmination of previous efforts and marks a critical starting point for transforming scientific research into national productive forces [1] Group 2: Product Development - Fluorine-18 Betazide is a new drug with complete independent intellectual property rights, developed by a team led by Professor Cui Mengchao from Beijing Normal University [1] - The drug has shown significant improvements in clinical applications, particularly in reducing non-specific uptake in brain white matter compared to similar products approved by the FDA [1] Group 3: Industry Context - The nuclear medicine industry is currently experiencing a golden development period, positioning Yuanzi Gaoke as a core player in the field due to its deep industry experience and distinctive characteristics [1] - The partnership aims to accelerate the clinical transformation of core results and build a talent cultivation pathway, contributing to the high-quality development of China's nuclear medicine sector [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1763） 於其他海外監管市場發佈的公告 中國同輻附屬公司與北京師範大學簽署氟[18F]貝他嗪一類創新 核藥專利轉讓協議及產學研項目合作協議 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條的規定而發出。 於本公告日期，董事會成員包括執行董事肖亞飛先生、張軍旗先生、霍穎穎女士 及馬曉宇女士；非執行董事陳贊先生、丁建民先生及常晉峪女士；及獨立非執行 董事潘昭國先生、陳景善女士、盧闖先生及安銳先生。 公告编号：2025-059 证券代码：430005 证券简称：原子高科 主办券商：广发证券 以下公告的中文原稿由中國同輻股份有限公司旗下一間於全國中小企業股份轉讓 系統上市的附屬公司，原子高科股份有限公司（股份代號：430005）於中國境內發 佈 ...

类别 公司 新股活动 京东工业 (招股中) 宝济药业-B (招股中) 天域半导体 (上市日) 遇见小面 (上市日) 业绩公布日 环球友饮智能 中国来骑哦 股东大会召开日 中国海洋石油 交通银行 迪诺斯环保 超人智能 云知声 瓦普思瑞元宇宙 重庆农村商业银行 盈健医疗 贵州银行 阳光纸业 分红派息 南旋控股 （除净日） 福禄控股 （派息日） 农业银行 （除净日） 白花油 （派息日） 白花油 （派息日） 比优集团 （派息日） 智通财经APP获悉，2025年12月5日，港股上市公司投资日志如下： ...

Core Insights - The Chinese nuclear technology application industry is transitioning from a "follower" to a "leader" position, with significant advancements in key isotopes and domestic medical equipment [1][2] - The market for radioactive drugs is projected to grow from 9.3 billion yuan in 2025 to 26 billion yuan by 2030, indicating strong growth potential [3][4] Industry Developments - The successful domestic production of Lu-177 isotope marks a significant milestone, enabling targeted therapies for prostate cancer and neuroendocrine tumors, with annual production capacity meeting domestic demand [2][3] - Over 90 types of radiation therapy equipment have been approved for market, with domestic brands accounting for over 70% of the market share, reducing reliance on imports [2][3] Market Potential - The radioactive drug market is expected to grow significantly, with projections indicating a rise from 9.3 billion yuan in 2025 to 26 billion yuan by 2030 [3] - Nuclear technology applications are expanding beyond healthcare into industrial and agricultural sectors, driving modernization and growth [3] Policy and Support - The "Three-Year Action Plan for High-Quality Development of the Nuclear Technology Application Industry (2024-2026)" aims for an annual economic output of 400 billion yuan by 2026, supported by legal frameworks and national research facilities [4] - The establishment of a national-level isotope supply base is part of the strategy to enhance supply chain resilience and reduce dependency on single sources [7][8] Challenges and Solutions - The industry faces challenges such as single-point dependency risks for key isotopes and insufficient supply chain elasticity, which could impact stability in nuclear medicine and industrial applications [5][6] - A "Strong Chain Action Plan" has been initiated to address these challenges, focusing on collaborative efforts among state-owned enterprises, research institutions, and private companies to enhance the entire industry chain [7][8] Future Outlook - The nuclear technology application industry is expected to maintain a compound annual growth rate of over 10%, with a target output of 600 billion yuan by the end of the 14th Five-Year Plan [7] - The integration of nuclear technology with AI and new materials is anticipated to create significant new value, potentially exceeding 100 billion yuan during the 14th Five-Year Plan period [8]

Core Insights - The Chinese nuclear technology application industry is transitioning from a "follower" to a "leader" position, particularly in the nuclear medical field, with significant advancements in the supply of key isotopes and domestic market share of radiation therapy equipment [1][2][3] - The market for radioactive drugs is projected to grow from 9.3 billion yuan in 2025 to 26 billion yuan by 2030, indicating strong growth potential in the nuclear medical sector [3] - The "Nuclear Technology Application Industry High-Quality Development Three-Year Action Plan (2024-2026)" aims for the industry to achieve a direct economic output of 400 billion yuan by 2026, with a target of 600 billion yuan by the end of the 14th Five-Year Plan [3][5] Achievements - The successful production of Lu-177 isotope by Qinshan Nuclear Power, which is expected to meet domestic market needs for targeted cancer therapies, marks a significant milestone in self-sufficient isotope supply [1][4] - Over 90 radiation therapy devices have been approved for market use by the National Medical Products Administration, with more than 70% being domestic brands, reducing reliance on imports [2] - The development pipeline for new radioactive drugs has accelerated, with over 200 candidates entering clinical trials, enhancing treatment options for cancer [2] Challenges - The industry faces risks related to single-point dependency on key isotopes and insufficient elasticity in the supply chain, which could jeopardize stability in nuclear medicine and industrial applications [4] - There is a lack of understanding among small and medium enterprises regarding national support policies, leading to difficulties in seizing development opportunities [4] - Issues such as insufficient investment in basic research, weak pilot testing for technology transfer, and imbalanced regional development are hindering overall industry progress [4] Strategic Initiatives - The "Strong Chain Action Plan" was launched to address existing challenges and promote a systematic upgrade of the nuclear technology application industry, involving collaboration among state-owned enterprises, research institutions, and private companies [5][6] - The plan emphasizes a collaborative approach to enhance the entire industry chain, ensuring the stability of domestic isotope supply and fostering innovation through cross-sector integration [6] - The initiative aims to create industrial clusters in key regions to address developmental imbalances and stimulate growth across the industry [6]

Core Insights - The integration of AI and nuclear technology is driving a significant transformation in the nuclear technology application industry, which has a market size of several hundred billion yuan and an annual growth rate exceeding 15% [1] - This convergence is expected to enhance efficiency, precision, and expand application scenarios across various sectors of the national economy [1] Group 1: AI and Nuclear Technology in Public Safety - AI-enabled nuclear technology is revolutionizing public safety, particularly in security checks, by improving efficiency and convenience for travelers [2] - The intelligent security system developed by Tongfang Weishi for Hong Kong International Airport exemplifies this integration, utilizing AI algorithms for efficient collaboration among various security devices [2] - The new security solution is projected to simplify the security process significantly by 2026, allowing travelers to keep liquids and gels in their bags, thus enhancing the overall experience [2] Group 2: Food Safety and Quality Enhancement - The fusion of AI and nuclear technology is addressing traditional challenges in food safety, particularly in non-destructive testing methods [3] - The durian quality CT detection system represents a significant advancement, allowing for non-invasive inspection of durians, thus eliminating the "blind box" market issue [3] - This technology boasts an accuracy rate exceeding 98%, which is 40 times more accurate than manual inspections [3] Group 3: Advancements in New Energy Sector - The integration of AI and nuclear technology is also showing strong potential in the new energy sector, particularly in lithium battery quality assurance [4] - Tongfang Weishi's technology can identify micron-level defects, thereby reducing the risk of battery fires and enhancing safety [4] - Collaborations with leading lithium battery manufacturers like CATL highlight the practical applications of this technology [4] Group 4: Market Expansion and Future Directions - The new industrialization strategy encompasses multiple dimensions, including technology, manufacturing, and quality, providing a broad market space for nuclear technology applications [5] - Challenges such as insufficient industrialization and innovation capabilities, as well as a shortage of interdisciplinary talent, need to be addressed for future development [6] - Key strategic directions include enhancing top-level planning, implementing action plans for high-quality development, and fostering innovation through collaborative efforts [6] Group 5: Key Companies in Nuclear Technology - Tongfang Co., Ltd. (600100) is a leader in security checks, providing solutions that integrate radiation imaging and AI for various applications [7] - China General Nuclear Power Corporation (000881) focuses on non-power nuclear technology applications, including industrial irradiation and medical accelerators [7] - China Nuclear Power (601985) operates multiple nuclear power plants and leverages group resources for nuclear technology applications [7]

Core Insights - The integration of AI and nuclear technology is driving a significant transformation in the nuclear technology application industry, which has a market size of several hundred billion yuan and an annual growth rate exceeding 15% [1] - AI is enhancing the efficiency and precision of nuclear technology applications across various sectors, including public safety, food safety, and new energy [1][5] Group 1: AI and Nuclear Technology in Public Safety - The combination of AI and nuclear technology is revolutionizing traditional security checks, improving efficiency and convenience for travelers [2] - The intelligent security system developed by Tongfang Weishi for Hong Kong International Airport exemplifies this integration, significantly increasing the throughput of security checks from 240 to 360 passengers per hour, a 50% efficiency improvement [2] - The new security solutions are expected to be fully implemented by 2026, allowing travelers to keep liquids and gels in their bags, thus simplifying the security process [2] Group 2: AI and Nuclear Technology in Food Safety - The fusion of AI and nuclear technology is addressing traditional challenges in food safety testing, particularly in non-destructive testing methods [3] - The durian quality CT detection system represents a significant advancement, achieving over 98% accuracy in quality grading, which is 40 times more accurate than manual inspections [3] Group 3: AI and Nuclear Technology in New Energy - In the new energy sector, Tongfang Weishi is utilizing industrial CT imaging technology combined with AI to create a quality assurance system for lithium batteries, capable of identifying micron-level defects [4] - This technology aims to reduce the risk of battery fires and has established partnerships with leading lithium battery manufacturers [4][5] Group 4: Market Expansion and Challenges - The new industrialization efforts in China are creating direct demand and broad market opportunities for nuclear technology applications, particularly in manufacturing upgrades and digital economy development [6] - Challenges such as insufficient industrialization and innovation capabilities, interdisciplinary collaboration issues, and talent shortages need to be addressed for future growth [6] - Key strategic directions include enhancing top-level planning, implementing regulatory frameworks, focusing on technological breakthroughs, and promoting open cooperation [6] Group 5: Key Companies in Nuclear Technology - Tongfang Co., Ltd. (600100) is a leader in security checks, providing solutions that integrate radiation imaging and AI for various applications [8] - China General Nuclear Power Corporation (000881) focuses on non-power nuclear technology applications, including industrial irradiation and medical accelerators [8] - China National Nuclear Corporation (01763.HK) specializes in medical isotopes and nuclear medical equipment, while China Nuclear Power (601985) operates multiple nuclear power plants [8]